J7601 Insurance Policy Changes

HCPCS J7601 is officially defined as "Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg." HCPCS J7601 is referenced in 3 tracked payer policy changes from Nevada Medicaid and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7601 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.